AMAG Pharmaceuticals Provides Update on FDA's Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)

Author's Avatar
Oct 06, 2020
Article's Main Image
  • The product remains on the market
  • AMAG has 15 days to respond to the FDA
  • AMAG continues to expect its recently announced tender offer and merger to close in November 2020